{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-006230","form_type":"8-K","ticker":"BBLG","cik":"0001419554","company_name":"Bone Biologics Corp","filed_at":"2022-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.396252+00:00","generated_at":"2026-06-27T00:42:59.781077+00:00","sec_items":["1.01","5.03","3.1","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bone Biologics secures exclusive DBM supply from MTF for rhNELL-1 spine fusion product","bullets":["Exclusive supply agreement with MTF Biologics for demineralized bone matrix (DBM) as carrier for rhNELL-1 bone graft substitute.","DBM will supply planned 30-patient pilot study and subsequent U.S. pivotal study in spine fusion.","Five-year term with extension option; targeting the $3 billion spine fusion market.","Also amended bylaws: stockholders with 15% voting power can call special meetings; exclusive Delaware forum for certain actions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-006230","json":"https://secwatch.observer/filing/0001493152-22-006230.json","markdown":"https://secwatch.observer/filing/0001493152-22-006230.md","text":"https://secwatch.observer/filing/0001493152-22-006230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419554/000149315222006230/0001493152-22-006230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419554/000149315222006230/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:42:59.781077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}